A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity

Part of paid clinical trials in Daytona Beach, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT07232732
Phase
PHASE1
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.

Key Dates

Start date
Oct 27, 2025
Status verified
May 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3549492 (Treatment Group 1)
    LY3549492 administered orally.
  • Experimental: LY3549492 (Treatment Group 2)
    LY3549492 administered orally.
  • Experimental: LY3549492 (Treatment Group 3)
    LY3549492 administered orally.
  • Experimental: LY3549492 (Treatment Group 4)
    LY3549492 administered orally.

Primary Outcome Measure

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through end of the Follow-up Period (Week 10) ]

Locations (3)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research UnitDaytona BeachFlorida32117-
Fortrea Clinical Research UnitDallasTexas75247-
Fortrea Clinical Research UnitMadisonWisconsin53704-

Find similar trials in Daytona Beach, FL

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Fortrea Clinical Research Unit· Daytona Beach, FLFortrea Clinical Research Unit· Dallas, TXFortrea Clinical Research Unit· Madison, WI

Related Studies